• Trump plans to sign an executive order this week to federalize AI regulation, arguing it's necessary for U.S. competitiveness.
  • The move aims to preempt state-level AI frameworks, potentially lowering compliance costs for tech firms operating nationwide.
  • Parallel efforts include HHS and FDA initiatives to embed AI into health regulation and internal operations, signaling heightened federal demand.

Donald Trump is set to sign a "One Rule" executive order this week to centralize U.S. artificial intelligence regulation under Washington, framing it as critical for maintaining the nation's leadership in the global AI race. According to people familiar with the matter, the order will establish a unified federal rulebook, overriding divergent state-level approval regimes that Trump claims could stifle innovation by requiring companies to navigate 50 separate processes.

"There must be only One Rulebook for AI," Trump posted, adding that the U.S. is currently "beating all countries" but risks losing its edge if states pursue their own frameworks. This move aligns with broader administration efforts to embed AI across federal agencies, including health and drug regulation, where recent developments have accelerated deployment timelines.

In parallel, the U.S. Department of Health and Human Services has rolled out a new AI strategy, citing Trump's Executive Order 14179 on removing barriers to American leadership as a foundation. The FDA has also launched an internal "agentic AI" platform for all employees, shifting from scattered pilots to a coordinated, agency-wide capability. These initiatives reflect a push to make AI a central driver in improving efficiency and patient outcomes, with HHS committing to public AI use-case inventories and risk evaluations to build trust.

Efforts to streamline AI governance have hit a snag in some sectors due to regulatory complexity, but HHS is attempting to speed deployment by accelerating security approvals while aligning with NIST cybersecurity controls. "What institutional investors like us are really focused on is regulatory stability," said a source close to the discussions, echoing sentiments from tech industry stakeholders who anticipate simpler national compliance but stronger federal oversight.

Without a deal to centralize regulation, companies could face fragmented compliance burdens that slow innovation, according to analysts. The administration's approach emphasizes a dual track of deployment and risk assessment in parallel, rather than waiting for perfect frameworks, which may set a precedent for other departments. Attempts to reach out to HHS for further comment were unsuccessful at press time.

In the short term, if signed as described, the order would quickly consolidate AI regulatory authority, limiting state experimentation. AI and tech firms are likely to focus on shaping the federal rulebook through lobbying, with healthcare vendors poised to benefit from clearer signals in agency adoption. Long term, a unified regime could accelerate national-scale AI roll-outs, though the quality of federal rules will determine impacts on innovation and safety.

This article was updated to clarify that the FDA's platform is for internal use only.